Welcome to our dedicated page for RHCCF news (Ticker: RHCCF), a resource for investors and traders seeking the latest updates and insights on RHCCF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect RHCCF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of RHCCF's position in the market.
Royal Helium (TSXV: RHC) (OTCQB: RHCCF) has announced its decision to issue 19,446,667 common shares at $0.030 per share to satisfy interest payments on two convertible debentures. The company will issue 9,846,667 shares for the 14% Debentures ($4,220,000 principal) and 9,600,000 shares for the 12% Debentures ($4,800,000 principal). The interest payments amount to $295,400 for the 14% Debentures and $288,000 for the 12% Debentures, both due December 31, 2024. This share issuance is subject to TSX Venture Exchange approval and follows the terms of debenture indentures dated February 8 and June 12, 2023.
